We hypothesize that the quality of diabetes treatment, measured as glycaemic control, is worse in patients with T2DM and colorectal- and breast cancer treated with curative intent, compared to T2DM patients without cancer, at 1 and 2 years after…
ID
Bron
Verkorte titel
Aandoening
Type 2 diabetes (T2DM)
Breast cancer/borstkanker
Colorectal cancer/colorectale kanker
Hypertension/hypertensie
Dyslipidemia/dyslipidemie
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The proportion of patients who achieve their individual treatment goal at 0, 12 months and 24 months after cancer diagnosis and treatment compared to baseline.
Achtergrond van het onderzoek
This pilot study is part of a prospective cohort study, using data from the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort and data concerning cancer from the Dutch Cancer Registry (NKR). Little is known about glycaemic control in patients who have received cancer treatment with curative intent. The aim of this project is to investigate the quality of diabetes care of type 2 diabetes patients with breast of colorectal cancer compared to those without cancer.
Patients participating in this study are diagnosed with T2DM and are treated in primary care in the Netherlands. In addition, they are diagnosed with primary breast- or colorectal cancer. For this study information about HbA1c, cholesterol/HDL ratio, blood pressure, diabetic medication use and cancer treatment were collected.
Doel van het onderzoek
We hypothesize that the quality of diabetes treatment, measured as glycaemic control, is worse in patients with T2DM and colorectal- and breast cancer treated with curative intent, compared to T2DM patients without cancer, at 1 and 2 years after cancer treatment.
Onderzoeksopzet
The follow-up time will start at 1 year before cancer diagnosis (baseline) and the primary and secondary outcomes will be analysed at 0, 12 and 24 months after cancer diagnosis.
Onderzoeksproduct en/of interventie
-
Publiek
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Wetenschappelijk
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients with type 2 diabetes treated in primary care, who are diagnosed with primary breast- or colorectal cancer, between 1999 and 2012 and who are treated with curative intent. Curative intent for breast cancer was defined as stage 1 to 3 breast cancer or ductal carcinoma in situ (DCIS) of the breast. Curative intent for colorectal cancer was defined as stage 1 to 3, who received at least surgical treatment.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Patients with evidence of relapse, patients with other cancers than breast or colorectal cancer, or patients with a history of other cancers prior to breast or colorectal cancer with the exception for non-melanoma skin cancer and patients who received no cancer treatment or only hormone treatment in breast cancer are excluded. Patients without at least 1 year of follow-up in the ZODIAC study prior to the diagnosis of breast or colorectal cancer are also excluded.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5533 |
| NTR-old | NTR5652 |
| Ander register | 13.0765 : METC |